in a nutshell

DelSiTech is an innovative drug delivery and development company that works with its partners to turn their active agents into novel and commercially attractive therapeutic drug products.

DelSiTech provides the technology and expertise for solving drug delivery problems. The company’s technology is based on amorphous silica (SiO2) matrix and sol-gel encapsulation technique which have significant competitive advantages over other technologies.

In addition, the Company is developing its own pipeline of supergeneric/505(b)(2) products to address significant unmet medical and commercial needs. The lead product, a long acting antiviral product for hepatitis B, will enter the clinic in 2021.

Our values

Our partners come first. We appoint our top teams to all projects and we are committed to exceed expectations. Our virtues, trust and collaboration ensure close co-operation with biotech and pharma partners and the opportunity to adapt to all their needs.

We encourage an entrepreneurial culture that ensures that our teams are agile, innovative and produce high-quality solutions. We are guided by a long-term vision to provide the best solutions to our partners. Our stable business environment enables us to make long-term investments in all of our working relationships; we can be a continuous partner throughout the development of a product.


DelSiTech aims to become a significant player in the area of controlled release supergeneric/505(b)(2) product development. The Company has a growing pipeline of first-in-class and differentiated products with improved patient compliance. In addition, DelSiTech aims to become the partner of choice for biotech and pharma companies seeking for the best solution for their drug delivery needs.

The Company strategy is to 1) Partner and license its biodegradable silica based drug delivery technology to biotech and pharma industry companies, 2) Develop and commercialize the first in-house controlled release drug product for hepatitis B, and 3) Explore and identify other business opportunities for the silica technology with significant market potential to provide a continuous flow of novel products in the future.


Örjan H. Andersson, D. Sc (Tech)
Örjan H. Andersson, D. Sc (Tech)Chairman of the Board
Dr. Andersson is founder and chairman of the Board of Bioxid Ltd, one of the major shareholders of DelSiTech. He is Doctor of Science in Technology. He has a strong research background in the biomaterials field and is adjunct professor at Åbo Akademi University. Member of the Swedish Academy of Engineering Sciences in Finland STV. Also former Director of Turku Biomaterials Center. Currently President of Novia University of Applied Sciences. Member or chair of the board of several companies.
Sebastian Björkstén
Sebastian BjörksténMSc, Member of the Board.
Mr. Björkstén is the Managing Director of several Finnish companies in the consumer business segment.
Jouni Heikkilä, MD, PhD
Jouni Heikkilä, MD, PhDMember of the Board.
Dr. Heikkilä has more than 25 years of experience of clinical practice and researchrelated to biomaterials and orthpedics. He is the Co-Founder and the Member of the Board of several companies. He is Specialistin orthopaedics and traumatology and Director of Traumatri Oy.
 Reijo Salonen, MD, PhD
Reijo Salonen, MD, PhDMember of the Board
Prof. Salonen, specialist in neurology, is the former Vice President, Head of R&D and Chief Medical Officer of Orion Pharma. He has more than 25 years experinece in drug development, especially in clinical development and medical affairs in international pharma industry.
Harry Jalonen, PhD, MBA
Harry Jalonen, PhD, MBAMember of the Board
Dr. Jalonen is the founder and former CEO of DelSiTech Ltd. He has more than 30 years of experience from the pharmaceutical and biotechnology industries. He is the co-founder and the Member of the Board of several biotechnology companies.
Kalle Öhman, MSc (Econ), CEFA
Kalle Öhman, MSc (Econ), CEFAMember of the Board
Mr. Öhman is the Managing Director of Avohoidon Tutkimussäätiö sr. a foundation that grants funding to medical research and invests in healthcare and biotechnology. He is also a Venture Partner in Voima Ventures a technology VC fund focused on cutting edge deep technology innovators. He has 18 years of entrepreneurial and investment experience in the healthcare and biotechnology industries.

Management Team

DelSiTech has at its disposal a world-class organization that has successfully taken pharmaceutical and biomaterial products to the market.

Dr. Lasse LeinoPhD, Chief Executive Officer
Dr. Leino is the company’s President and Chief Executive Officer and has more than 20 years life science business experience. He is the founder and former President and CEO of BioCis Pharma Ltd as well as the first CEO and COO of Laurantis Pharma Ltd. Previously, Dr. Leino has worked in various R&D management positions in Orion Pharma, BioTie Therapies Ltd, and AstraZeneca in Lund, Sweden. Dr. Leino holds a PhD in biochemistry and has a position as Adjunct Professor in immunology at the University of Turku, Finland.
Dr. Mika JokinenDSc, Research Director
Dr. Jokinen is a co-founder of DelSiTech and Research Director of in the company since 2006. In addition, he is a Principal Lecturer in chemical and biochemical engineering at the Turku University of Applied Sciences. He has over 20 years R&D experience in silica-based biomaterials. Dr. Jokinen holds a Doctor of Science in Technology and has a position as Adjunct Professor in Medical Biomaterials at Åbo Akademi University, Turku, Finland.
Dr. Sakari Karhuvaara MD, Medical Director
Dr. Karhuvaara serves as Medical Director in DelSiTech. He has over 30 years of experience in clinical research and development and consulting in the pharma industry. He has also been active in primary and occupational health care, both as a practicing physician and as a developer of the health care delivery systems.
Dr. Frederic DargelasPhD, MBA, Head of Business Development and Alliance Management
Dr. Frederic Dargelas is the Director, Head of Business Development and Alliance Management of DelSiTech. He joined the company in 2019. Dr. Dargelas is a business development and R&D veteran with almost 20 years of experience in the pharma and biotech industry. Previously, he held managing positions at diverse international companies such as GSK and Orion Pharma. Dr. Dargelas holds a PhD in Physical Chemistry of Polymers and an MBA.
Dr. Marceline Akieh-PirkanniemiDirector, Head of Analytical Development
Dr. Marceline Akieh-Pirkanniemi serves as the Director, Head of Analytical Development in DelSiTech. She joined the DelSiTech team in January 2020. Dr. Akieh has over a decade of leading experience in applications of analytical science within the private sector, as well as in academia. She has significant prior expertise with analytics focused on both non-biodegradable and biodegradable drug delivery systems through positions as an analytical specialist. Dr. Akieh holds a PhD in Analytical Chemistry.
Dr. Hanna ArstilaDirector, Head of Formulation Development
Dr. Hanna Arstila serves as the Director, Head of Formulation development at DelSiTech. Having joined the DelSiTech team in October 2020, Dr. Arstila has a strong background in biomaterial science and a decade of experience in industrialization, product life-cycle management, production operations and leadership through previous roles at Orion Pharma. Critically, Dr. Arstila also commands an in depth knowledge of GMP operations, LEAN Six Sigma and holds a PhD in Inorganic Chemistry.